JAK2 and myeloproliferative neoplasm: In summary, this study suggests JAK2 independent activation of ERK can be induced by JAK2 inhibitors and may function as a compensatory mechanism employed by MPN cells to survive in the presence of JAK2 inhibition, thereby reducing effectiveness of anti-JAK2 targeted therapies.